Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. more
Time Frame | SRZN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.6% | -3.39% | 0.2% |
1-Month Return | 12.8% | -1.92% | 2.72% |
3-Month Return | 15.96% | -10.54% | 7.31% |
6-Month Return | -13.45% | -4.47% | 10.44% |
1-Year Return | 16.24% | 4.06% | 27.53% |
3-Year Return | -90.31% | 0.94% | 30.88% |
5-Year Return | -93.72% | 36.67% | 89.21% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 12.50M | 12.50M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | 2.93M | 3.30M | 3.27M | 27.23M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":10.76,"profit":true},{"date":"2021-12-31","value":12.11,"profit":true},{"date":"2022-12-31","value":12.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (2.93M) | (3.30M) | 12.50M | (27.23M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-23.43,"profit":false},{"date":"2021-12-31","value":-26.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-217.84,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | 100.00% | (217.84%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-217.84,"profit":false}] |
Operating Expenses | 24.81M | 32.81M | 54.39M | 56.84M | 18.55M | [{"date":"2019-12-31","value":43.64,"profit":true},{"date":"2020-12-31","value":57.72,"profit":true},{"date":"2021-12-31","value":95.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.64,"profit":true}] |
Operating Income | (25.11M) | (32.81M) | (54.39M) | (44.34M) | (45.78M) | [{"date":"2019-12-31","value":-2510600000,"profit":false},{"date":"2020-12-31","value":-3280700000,"profit":false},{"date":"2021-12-31","value":-5439100000,"profit":false},{"date":"2022-12-31","value":-4433900000,"profit":false},{"date":"2023-12-31","value":-4578000000,"profit":false}] |
Total Non-Operating Income/Expense | - | 182.00K | (185.00K) | 9.12M | 5.04M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":2,"profit":true},{"date":"2021-12-31","value":-2.03,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.32,"profit":true}] |
Pre-Tax Income | (24.36M) | (32.72M) | (54.65M) | (36.00M) | (43.04M) | [{"date":"2019-12-31","value":-2436200000,"profit":false},{"date":"2020-12-31","value":-3271600000,"profit":false},{"date":"2021-12-31","value":-5464800000,"profit":false},{"date":"2022-12-31","value":-3600400000,"profit":false},{"date":"2023-12-31","value":-4304200000,"profit":false}] |
Income Taxes | - | (91.00K) | (2.14M) | (8.34M) | 2.75M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3.31,"profit":false},{"date":"2021-12-31","value":-77.69,"profit":false},{"date":"2022-12-31","value":-302.87,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | (32.63M) | (52.51M) | (27.67M) | (45.79M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3262500000,"profit":false},{"date":"2021-12-31","value":-5251000000,"profit":false},{"date":"2022-12-31","value":-2766900000,"profit":false},{"date":"2023-12-31","value":-4579400000,"profit":false}] |
Income From Continuous Operations | - | (32.72M) | (54.65M) | (36.00M) | (34.90M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3271600000,"profit":false},{"date":"2021-12-31","value":-5464800000,"profit":false},{"date":"2022-12-31","value":-3600400000,"profit":false},{"date":"2023-12-31","value":-3490400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (24.36M) | (32.63M) | (52.51M) | (27.67M) | (43.04M) | [{"date":"2019-12-31","value":-2436200000,"profit":false},{"date":"2020-12-31","value":-3262500000,"profit":false},{"date":"2021-12-31","value":-5251000000,"profit":false},{"date":"2022-12-31","value":-2766900000,"profit":false},{"date":"2023-12-31","value":-4304200000,"profit":false}] |
EPS (Diluted) | - | - | (1.80) | (1.04) | (5.54) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-180,"profit":false},{"date":"2022-12-31","value":-104,"profit":false},{"date":"2023-12-31","value":-554,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SRZN | |
---|---|
Cash Ratio | 5.07 |
Current Ratio | 7.40 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SRZN | |
---|---|
ROA (LTM) | -32.65% |
ROE (LTM) | -173.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SRZN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.88 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.12 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SRZN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.09 |
P/B | 5.46 |
Price/FCF | NM |
EV/R | 0.15 |
EV/Ebitda | 0.71 |
Surrozen Inc (SRZN) share price today is $9.985
Yes, Indians can buy shares of Surrozen Inc (SRZN) on Vested. To buy Surrozen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SRZN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Surrozen Inc (SRZN) via the Vested app. You can start investing in Surrozen Inc (SRZN) with a minimum investment of $1.
You can invest in shares of Surrozen Inc (SRZN) via Vested in three simple steps:
The 52-week high price of Surrozen Inc (SRZN) is $16.19. The 52-week low price of Surrozen Inc (SRZN) is $6.
The price-to-earnings (P/E) ratio of Surrozen Inc (SRZN) is
The price-to-book (P/B) ratio of Surrozen Inc (SRZN) is 5.46
The dividend yield of Surrozen Inc (SRZN) is 0.00%
The market capitalization of Surrozen Inc (SRZN) is $32.50M
The stock symbol (or ticker) of Surrozen Inc is SRZN